Jacobs Levy Equity Management
FBRX icon

Jacobs Levy Equity Management’s Forte Biosciences FBRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-166
Closed -$416K – 945
2019
Q2 		$416K Sell
166
-70
-30% -$208K 0.01% 769
2019
Q1 		$963K Buy
236
+79
+50% +$305K 0.01% 670
2018
Q4 		$482K Sell
157
-9
-5% -$38.8K 0.01% 737
2018
Q3 		$970K Buy
166
+34
+26% +$129K 0.01% 652
2018
Q2 		$463K Buy
+132
New +$483K 0.01% 814

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobs Levy Equity Management's FBRX Position: Q3 2019 in Review

Jacobs Levy Equity Management sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 166 shares — an estimated $416K sold.

Jacobs Levy Equity Management first reported a position in FBRX in Q2 2018 and held it in 5 quarters. The position peaked at $970K in Q3 2018. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • Jacobs Levy Equity Management reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 166 Forte Biosciences shares in Q3 2019, an estimated $416K.
  • Jacobs Levy Equity Management first reported a position in Forte Biosciences in Q2 2018 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Forte Biosciences position peaked at $970K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2019, filed 14 Nov 2019.